Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hikma Launches Nasal Naloxone Spray In US

Emergency Opioid Overdose Treatment Approved Through 505(b)(2) Pathway

05 Aug 2021

• By Dave Wallace

Nose Nasal Nostrils — Hikma has launched its Kloxxado naloxone nasal spray in the US • Source: Alamy

Related Content

Hikma Has A First With Labetalol Launch In US

02 Jun 2021

Hikma Has A Trio Of US Launches

29 Jun 2021

Hikma Resumes Launch Of Advair Rival

21 Apr 2021

Advair Relaunch And Nasal Naloxone Nod Raise Hikma’s Expectations

30 Apr 2021

Hikma Introduces A Pair Of US Injectables

10 May 2021

Hikma Fails To Nix Vascepa Induced Infringement Case Early On

04 Aug 2021

Hikma Snaps Up Insys Sprays As Part Of US Drive Towards Differentiation

14 Aug 2019

Related Companies

Hikma Pharmaceuticals plc

Additional Topics

Launches Value-Added Medicines Strategy Sales & Earnings BioPharmaceutical

More from Products

More from Generics Bulletin

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.